2024年度董事会工作报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2024年，哈尔滨誉衡药业股份有限公司（以下简称"公司"）董事会严格按 照《公司法》、《证券法》、《深圳证券交易所股票上市规则》、《深圳证券交 易所上市公司自律监管指引第1号——主板上市公司规范运作》、《公司章程》 及《董事会议事规则》等有关法律法规及公司相关制度的规定，切实履行股东大 会赋予的董事会职责，严格执行股东大会各项决议，勤勉尽责地开展各项工作， 积极推进董事会各项决议的实施，不断规范公司法人治理结构，维护公司和全体 股东的合法权益。现将公司董事会2024年度工作情况汇报如下： 哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-031 哈尔滨誉衡药业股份有限公司 一、董事会日常工作情况 ㈠ 董事会会议召开情况 2024年度，董事会共召开8次会议，累计审议了40项议案。所有会议召开都 能按照程序及规定进行，所有会议的决议都合法有效。董事会会议召开的具体情 况如下表： | 序 号 | | | 届次 | 时间 审议通过的议案情况 | | | ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-048 哈尔滨誉衡药业股份有限公司 关于提请 2024 年年度股东大会授权董事会 办理小额快速融资相关事宜的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 4 月 24 日，哈尔滨誉衡药业股份有限公司（以下简称"公司"）第 七届董事会第三次会议审通过了《关于提请 2024 年年度股东大会授权董事会办 理小额快速融资相关事宜的议案》，具体情况如下： 一、关于提请 2024 年年度股东大会授权董事会办理小额快速融资的相关事 宜 根据《上市公司证券发行注册管理办法》、《深圳证券交易所上市公司证券 发行上市审核规则》、《深圳证券交易所上市公司证券发行与承销业务实施细则》 等相关规定，公司董事会提请 2024 年年度股东大会授权董事会决定向特定对象 发行融资总额不超过人民币 3 亿元且不超过最近一年末净资产 20%的股票，授权 期限为 2024 年度股东大会通过之日起至 2025 年度股东大会召开之日止。本次授 权事宜包括以下内容： 1、确认公司是否符合以简易 ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-046 哈尔滨誉衡药业股份有限公司 关于召开 2024 年年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 4 月 24 日，哈尔滨誉衡药业股份有限公司（以下简称"公司"）第 七届董事会第三次会议审议通过了《关于召开 2024 年年度股东大会的议案》。现 就相关事宜公告如下： 一、召开会议基本情况 ㈠ 股东大会会议届次：2024 年年度股东大会。 ㈡ 会议召集人：公司董事会。 ㈢ 会议召开的合法、合规性：本次股东大会的召开已经公司第七届董事会 第三次会议审议通过，符合《公司法》、《公司章程》等相关规定。 ㈣ 召开时间： 1、现场会议时间：2025 年 5 月 16 日 15:00； 2、网络投票时间：2025 年 5 月 16 日； ⑴ 通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 5 月 16 日 9:15—9:25，9:30—11:30 和 13:00—15:00； ⑵ 通过深圳证券交易所互联网系统投票的具体时间为：2 ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-035 哈尔滨誉衡药业股份有限公司 第六届监事会第十八次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 4 月 14 日，哈尔滨誉衡药业股份有限公司（以下简称"公司"）董 事会办公室以电子邮件、短信的方式向全体监事发出了《关于召开第六届监事会 第十八次会议的通知》及相关议案。 2025 年 4 月 24 日，公司第六届监事会第十八次会议以现场结合通讯方式召 开。会议应出席监事 3 名，实际出席监事 3 名。会议由监事会主席张超先生主 持，会议的召集、召开及表决程序符合《公司法》、《公司章程》及《监事会议事 规则》等有关规定。 一、审议并通过了《关于 2024 年度报告全文及摘要的议案》，并发表如下意 见： 经审核，监事会认为董事会编制和审核公司 2024 年年度报告的程序符合法 律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了上市公 司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见同日披露于《中国证券报 ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-029 哈尔滨誉衡药业股份有限公司 第七届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 4 月 14 日，哈尔滨誉衡药业股份有限公司（以下简称"公司"） 董 事会办公室以短信及电子邮件的方式向全体董事发出了《关于召开公司第七届董 事会第三次会议的通知》及相关议案。 2025 年 4 月 24 日，第七届董事会第三次会议以现场结合通讯方式召开。本 次会议应参加董事 6 人，实际参加董事 6 人。会议的召集、召开及表决程序符合 《公司法》、《公司章程》及《董事会议事规则》等有关规定。会议由董事长沈 臻宇女士主持，经与会董事认真审议及表决形成如下决议： 一、审议并通过了《关于 2024 年度报告全文及摘要的议案》。 具体内容详见同日披露于《中国证券报》、《证券时报》及巨潮资讯网 http://www.cninfo.com.cn（以下简称"指定媒体"）的《2024 年年度报告摘要》、 《2024 年年度报告全文》。 本议案提交董事会前已 ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-036 哈尔滨誉衡药业股份有限公司 关于 2024 年度不进行利润分配的专项说明公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025年4月24日，哈尔滨誉衡药业股份有限公司（以下简称"公司"）第七届 董事会第三次会议、第六届监事会第十八次会议审议通过了《关于2024年度利润 分配预案的议案》。本议案尚需经公司2024年年度股东大会审议批准。具体情况 如下： 一、审议程序 2025年4月24日，公司第七届董事会第三次会议审议通过了《关于2024年度 利润分配预案的议案》。表决结果：同意6票，反对0票，弃权0票。董事会认为， 本次利润分配预案符合《公司章程》和《未来三年（2023-2025年）股东回报规划》 中对于利润分配的相关规定，具备合法性、合规性、合理性。同意将公司本次利 润分配预案提交至公司2024年度股东大会审议。 2025 年 4 月 24 日，公司第六届监事会第十八次会议审议通过了《关于 2024 年度利润分配预案的议案》。表决结果：同意 3 票，反 ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-042 哈尔滨誉衡药业股份有限公司 关于 2024 年限制性股票激励计划首次授予部分 第一个限售期解除限售条件成就的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、哈尔滨誉衡药业股份有限公司（以下简称"公司"）2024 年限制性股票 激励计划首次授予部分第一个限售期解除限售条件已经成就，本次符合解除限售 条件的激励对象共计 95 人，可解除限售的限制性股票数量为 27,997,600 股，约 占公司目前总股本的 1.2467%。 2、本次限制性股票办理完解除限售手续后、上市流通前，公司将披露限制 性股票上市流通的提示性公告，敬请投资者注意。 公司于 2025 年 4 月 24 日召开的第七届董事会第三次会议、第六届监事会第 十八次会议审议通过了《关于 2024 年限制性股票激励计划首次授予部分第一个 限售期解除限售条件成就的议案》。根据《上市公司股权激励管理办法》、《2024 年限制性股票激励计划（草案）》（以下简称"《激励计划》"）、《202 ...

北京植德律师事务所 关于 哈尔滨誉衡药业股份有限公司 2024 年限制性股票激励计划之 首次授予部分第一个限售期解除限售事宜的 法律意见书 植德(证)字[2024]002-6 号 二〇二五年四月 北京植德律师事务所 Merits & Tree Law Offices 北京市东城区东直门南大街 1 号来福士中心办公楼 12 层 邮编: 100007 12th Floor, Raffles City Beijing Office Tower, No.1 Dongzhimen South Street, Dongcheng District, Beijing 100007 P.R.C 电话(Tel) : 010-56500900 传真(Fax):010-56500999 www.meritsandtree.com 北京植德律师事务所 关于哈尔滨誉衡药业股份有限公司 2024 年限制性股票激励计划之 首次授予部分第一个限售期解除限售事宜的 法律意见书 植德(证)字[2024]002-6 号 致:哈尔滨誉衡药业股份有限公司 根据北京植德律师事务所(以下简称"本所")与哈尔滨誉衡药业股份有限 公司(以下简称"公司")签署 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 551,255,672.12, a decrease of 7.06% compared to CNY 593,133,301.68 in the same period last year[3] - Net profit attributable to shareholders increased by 15.24% to CNY 60,252,267.26, up from CNY 52,282,909.59 year-on-year[3] - The net profit after deducting non-recurring gains and losses rose by 54.74% to CNY 49,733,030.46, compared to CNY 32,140,693.96 in the previous year[3] - The company reported total operating revenue of ¥551,255,672.12 for the current period, a decrease from ¥593,133,301.68 in the previous period, reflecting a decline of approximately 7.1%[27] - The total profit for the current period is CNY 68,950,223.62, compared to CNY 68,413,553.70 in the previous period, reflecting a slight increase of 0.8%[28] - Operating profit for the current period is CNY 69,069,634.07, slightly up from CNY 68,449,052.90 in the previous period[28] - The net profit for the current period is CNY 61,931,584.62, an increase of 11.6% compared to CNY 55,761,035.49 in the previous period[28] - Basic earnings per share increased to CNY 0.0274 from CNY 0.0235, reflecting a growth of 16.6%[29] Cash Flow and Assets - The net cash flow from operating activities decreased by 33.14% to CNY 106,474,494.15, down from CNY 159,239,649.03 in the same period last year[3] - The cash flow from operating activities for the current period is CNY 106,474,494.15, down 33.1% from CNY 159,239,649.03 in the previous period[31] - The net cash flow from investment activities was negative CNY 112,950,739.92, a significant increase in outflow compared to negative CNY 4,756,664.99 in the previous year[13] - The company's cash and cash equivalents at the end of the reporting period amounted to ¥461,761,822.17, down from ¥481,962,600.35 at the beginning of the period, a decrease of approximately 4.5%[24] - The company's total assets at the end of the reporting period were CNY 2,878,651,000.44, reflecting a 1.90% increase from CNY 2,825,112,612.64 at the end of the previous year[3] - The company's total liabilities rose to ¥920,357,347.36 from ¥852,260,332.70, an increase of approximately 8.0%[26] Shareholder Information - The total number of common shareholders at the end of the reporting period is 87,994[15] - The top 10 shareholders hold a combined 18.12% of the total shares, with the largest shareholder, Shen Zhenyu, owning 4.92%[15] - Shen Zhenyu holds 110,490,000 shares, with 75% of these being locked-up shares[17] - The company repurchased a total of 32,307,224 shares from March 10 to March 13, 2025, accounting for 1.42% of the total share capital[18] - The highest transaction price during the repurchase was 2.51 RMB per share, and the total funds used for the repurchase amounted to 79,994,101.62 RMB[18] - The company has completed the repurchase and cancellation of 1,653,000 shares of restricted stock from eight departed incentive plan participants[21] Legal and Regulatory Matters - The company is involved in an ongoing lawsuit regarding a 42.12% equity transfer of Guangzhou Yuheng Biotechnology Co., Ltd., with a court ruling in favor of the company[20] - The company completed a board restructuring on February 6, 2025, during the first extraordinary shareholders' meeting[17] Research and Development - Research and development expenses increased to CNY 15,046,259.26 from CNY 14,704,935.33, representing a growth of 2.3%[28] - The company has received approval for its potassium chloride oral solution, enhancing its product offerings in the potassium supplementation market[22] - The company has not disclosed any new product or technology developments in the current reporting period[15] Market and Future Outlook - There are no indications of market expansion or mergers and acquisitions mentioned in the report[15] - The company has not provided specific future guidance or performance outlook in the current report[15] Financial Expenses and Investments - Financial expenses decreased by 82.43% to CNY 232,729.85, primarily due to a significant reduction in bank loans[10] - The company recorded a fair value change gain of CNY 3,559,330.01, a 131.21% increase compared to the previous year's loss[10] - The company’s long-term equity investments were valued at ¥68,143,581.25, slightly down from ¥68,292,921.95, indicating a minor decrease of about 0.2%[25] - The company’s inventory decreased to ¥185,855,538.43 from ¥188,671,540.43, reflecting a decline of approximately 1.4%[25]

Financial Performance - The net profit attributable to shareholders, excluding non-recurring gains and losses, reached 183.31 million RMB, a year-on-year increase of 243.42%[4] - The weighted average return on equity improved from 7.26% to 12.89%[4] - The net cash flow from operating activities was 411 million RMB, an increase of nearly 50% year-on-year[5] - The company's operating revenue for 2024 was CNY 2,440,732,030.17, a decrease of 7.06% compared to CNY 2,626,039,306.71 in 2023[28] - Net profit attributable to shareholders for 2024 reached CNY 232,759,457.12, representing a significant increase of 93.43% from CNY 120,334,186.37 in 2023[28] - The cash flow from operating activities for 2024 was CNY 410,935,803.11, up by 49.88% compared to CNY 274,175,284.57 in 2023[28] - The basic earnings per share for 2024 was CNY 0.1059, an increase of 93.60% from CNY 0.0547 in 2023[28] - The net assets attributable to shareholders increased by 17.39% to CNY 1,950,697,287.55 at the end of 2024, compared to CNY 1,661,773,347.48 at the end of 2023[28] - The company achieved a total revenue of 2.44 billion yuan, with a net profit of 233 million yuan, representing a year-on-year growth of 93.43%[58] Sales and Market Performance - Sales of the injectable multivitamin product increased by over 40%, while sales of the An Nao Wan/Pian product surged by over 90%[5] - The company achieved a sales growth of over 90% for its core product, An Nao Wan/Pill, which is now covered by over 3,900 hospitals and primary medical institutions[49] - The potassium chloride sustained-release tablet (Bu Da Xiu) holds a market share of 55.37% in urban retail pharmacies and 29.41% in public hospitals, ranking first and second in their respective segments[50] - The injection of multiple vitamins maintains a market share of over 80% and has been selected in multiple centralized procurement programs[51] - The company’s injection of deer melon peptide has a market share of 56.46% in public hospitals, leading its segment[51] - The company’s Ginkgo biloba injection has a stable market position with a 55.77% market share in public hospitals[52] Research and Development - The company has over 20 projects under research and has submitted more than 10 listing applications to the CDE, with 4 products approved[7] - The company launched five new research projects in key areas such as cardiovascular and orthopedic fields, with over 20 projects currently under development[59] - R&D investment increased by 8.80% to ¥97,008,551.90 in 2024, compared to ¥89,158,520.74 in 2023[74] - The number of R&D personnel rose by 13.33% to 102 in 2024, up from 90 in 2023[74] - The proportion of R&D investment to operating revenue increased to 3.97% in 2024 from 3.40% in 2023, a change of 0.57%[74] Financial Management and Cost Control - The company reduced financial expenses by 32.38 million RMB through early repayment of bank loans and improved capital efficiency[6] - Management expenses, excluding equity incentive costs, decreased by 18.29% year-on-year[6] - The asset-liability ratio decreased to 30%, the lowest in 10 years, indicating improved financial structure[6] - The company reported a significant reduction in financial expenses, decreasing by 103.41% to -¥1,067,714.14 due to reduced interest costs from loan repayments[71] - Sales expenses decreased by 25.82% to ¥792,647,941.82, while management expenses decreased by 4.85% to ¥166,704,878.22[71] Corporate Governance and Compliance - The company aims to enhance compliance and governance mechanisms, including the cancellation of the supervisory board and strengthening the audit committee's role[8] - The company has established a sound corporate governance structure, ensuring compliance with relevant laws and regulations, and maintaining the integrity of shareholder meetings[108] - The company maintains a strict internal audit system, with an audit committee composed of a majority of independent directors[114] - The company has a dedicated investor relations management system to enhance communication with investors[113] - The company is in compliance with the regulations set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange[138] Industry Outlook and Challenges - The pharmaceutical manufacturing industry faced challenges in 2024, with a total revenue of CNY 25,298.5 billion, remaining flat compared to 2023[38] - The company experienced a decline in total revenue due to ongoing price reductions in the pharmaceutical sector and increased competition[38] - The pharmaceutical industry in China is expected to maintain steady growth due to increasing demand driven by an aging population, rising income levels, and enhanced healthcare awareness[39] - The company faces industry policy risks that could impact sales and pricing, and it plans to adapt its business model accordingly[99] - The company faces significant risks in drug development due to increasing regulatory requirements and potential funding increases, which may lead to higher failure rates in drug projects[100] Environmental and Social Responsibility - The company is committed to improving its environmental protection and safety management systems to meet higher regulatory demands and fulfill corporate social responsibilities[103] - The company is classified as a key pollutant discharge unit in Harbin for 2024, adhering to environmental protection laws and standards[164] - The company has obtained pollution discharge permits for its subsidiaries, with validity extending until 2029[164] - The company has implemented a self-monitoring plan in accordance with the latest pollution discharge permit requirements[167] - The company has implemented emergency response plans for environmental incidents and has filed them accordingly[168] Employee Management and Development - The company has established a comprehensive employee care mechanism, including health management and customized insurance plans for different job roles[146] - The company has launched a talent development program, including a new employee training camp and a "Yuheng Talent Program" to enhance employee skills and loyalty[148] - The company has a dual career path system for employees, allowing for advancement in both management and professional tracks[150] - The company has implemented a health and wellness program, including annual health check-ups and psychological support services for employees[147] - The total number of employees at the end of the reporting period is 2,703, with 64 in the parent company and 2,639 in major subsidiaries[143] Legal and Regulatory Matters - The company is involved in a lawsuit regarding the sale of a 42.12% stake in Guangzhou Yuheng Biotechnology Co., with a claim of 117.6 million yuan for unpaid transfer fees[189] - The company received a civil judgment from the Beijing High Court, which upheld the original ruling, dismissing the appeal[190] - The company has received warning letters from the China Securities Regulatory Commission for issues related to compliance, with specific actions taken to address these concerns[191]